• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Chronic rhinosinusitis with nasal polyps: how to identify eligible patients for biologics in clinical practice.慢性鼻-鼻窦炎伴鼻息肉:如何在临床实践中确定适合使用生物制剂的患者。
Acta Otorhinolaryngol Ital. 2022 Feb;42(1):75-81. doi: 10.14639/0392-100X-N1699.
2
Reduced sinonasal levels of 1α-hydroxylase are associated with worse quality of life in chronic rhinosinusitis with nasal polyps.鼻窦中1α-羟化酶水平降低与伴鼻息肉的慢性鼻-鼻窦炎患者较差的生活质量相关。
Int Forum Allergy Rhinol. 2016 Jan;6(1):58-65. doi: 10.1002/alr.21576. Epub 2015 Nov 17.
3
Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis.评估未充分控制的慢性鼻-鼻窦炎伴鼻息肉患者疗效结局的临床有意义变化。
Laryngoscope. 2022 Feb;132(2):265-271. doi: 10.1002/lary.29888. Epub 2021 Dec 1.
4
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.奥马珠单抗治疗鼻息肉的疗效和安全性:两项随机 3 期临床试验。
J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7.
5
[Experience of biological therapy in severe forms of chronic rhinosinusitis with nasal polyps in the conditions of regional healthcare].[地区医疗条件下重度慢性鼻-鼻窦炎伴鼻息肉生物治疗的经验]
Vestn Otorinolaringol. 2023;88(2):51-58. doi: 10.17116/otorino20228802151.
6
Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice.慢性鼻-鼻窦炎伴鼻息肉患者的临床-细胞学分级和表型:临床实践中的相关性。
Monaldi Arch Chest Dis. 2020 Jun 23;90(2). doi: 10.4081/monaldi.2020.1277.
7
Chronic rhinosinusitis with nasal polyps management in the age of biologics.生物制剂时代的慢性鼻-鼻窦炎伴鼻息肉管理。
Allergy Asthma Proc. 2020 Nov 1;41(6):413-419. doi: 10.2500/aap.2020.41.200069.
8
Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps.慢性鼻-鼻窦炎伴鼻息肉患者的鼻-鼻窦结局测试(SNOT-22)领域的开发。
Laryngoscope. 2022 May;132(5):933-941. doi: 10.1002/lary.29766. Epub 2021 Aug 26.
9
[The perspectives of biologics in the treatment of chronic rhinosinusitis with nasal polyps].[生物制剂在治疗伴有鼻息肉的慢性鼻-鼻窦炎中的应用前景]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Nov;37(11):853-855. doi: 10.13201/j.issn.2096-7993.2023.11.001.
10
[Decision-making in the treatment of chronic rhinosinusitis with nasal polyps in the era of biologics].[生物制剂时代鼻息肉慢性鼻窦炎的治疗决策]
HNO. 2024 Apr;72(4):225-230. doi: 10.1007/s00106-024-01430-1. Epub 2024 Feb 20.

引用本文的文献

1
Histopathological parameters and immunoexpression of CD45RO (CLA) and CD68 in chronic rhinosinusitis with nasal polyps.伴鼻息肉的慢性鼻-鼻窦炎中组织病理学参数及CD45RO(CLA)和CD68的免疫表达
Rom J Morphol Embryol. 2024 Oct-Dec;65(4):655-660. doi: 10.47162/RJME.65.4.12.
2
Proposal of a New Composite Score (DAMADECO) to Simultaneously Evaluate Asthma and CRSwNP Severity in Comorbid Patients.一种用于同时评估合并症患者哮喘和慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)严重程度的新综合评分(DAMADECO)的提议
J Clin Med. 2025 Feb 2;14(3):957. doi: 10.3390/jcm14030957.
3
Patient-centered outcomes for clinical trials in chronic rhinosinusitis with or without nasal polyps and allergic fungal rhinosinusitis.伴有或不伴有鼻息肉的慢性鼻-鼻窦炎及变应性真菌性鼻-鼻窦炎临床试验的以患者为中心的结局
J Patient Rep Outcomes. 2025 Jan 23;9(1):11. doi: 10.1186/s41687-024-00833-6.
4
Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology.血清蛋白质组学分析揭示了嗜酸性粒细胞性慢性鼻-鼻窦炎伴鼻息肉病理生理学的生物标志物。
J Inflamm Res. 2024 Feb 7;17:805-821. doi: 10.2147/JIR.S444280. eCollection 2024.
5
Biologics for Chronic Rhinosinusitis-A Modern Option for Therapy.用于慢性鼻-鼻窦炎的生物制剂——一种现代治疗选择
Life (Basel). 2023 Nov 5;13(11):2165. doi: 10.3390/life13112165.
6
Eosinophil-mast cell pattern of intraepithelial infiltration as a marker of severity in CRSwNP.上皮内浸润的嗜酸性粒细胞-肥大细胞模式作为 CRSwNP 严重程度的标志物。
Sci Rep. 2023 Jul 26;13(1):12101. doi: 10.1038/s41598-023-39149-8.
7
Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence.聚焦于 IL-4/IL-13 受体阻滞剂在 CRSwNP 患者中的短期治疗:microRNAs 的调节作用和初步临床证据。
Genes (Basel). 2022 Dec 15;13(12):2366. doi: 10.3390/genes13122366.
8
Sinonasal Symptoms in COPD: Burden and Associations with Clinical Markers of Disease.COPD 患者的鼻窦症状:负担和与疾病临床标志物的关联。
Int J Chron Obstruct Pulmon Dis. 2022 Sep 7;17:2137-2147. doi: 10.2147/COPD.S372991. eCollection 2022.

本文引用的文献

1
Chronic rhinosinusitis with nasal polyposis: the role of personalized and integrated medicine.伴有鼻息肉的慢性鼻-鼻窦炎:个性化与整合医学的作用。
Monaldi Arch Chest Dis. 2021 Mar 8;91(3). doi: 10.4081/monaldi.2021.1769.
2
The clinical relevance of the clinical cytological grading in patients with chronic rhinosinusitis with nasal polyps.慢性鼻-鼻窦炎伴鼻息肉患者临床细胞学分级的临床相关性。
J Allergy Clin Immunol. 2020 Aug;146(2):462-463. doi: 10.1016/j.jaci.2020.04.049. Epub 2020 Jun 24.
3
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.度普利尤单抗:一种治疗慢性鼻-鼻窦炎伴鼻息肉的药物。
Drugs. 2020 May;80(7):711-717. doi: 10.1007/s40265-020-01298-9.
4
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.欧洲鼻窦炎和鼻息肉 2020 年立场文件。
Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
5
Olfactory dysfunction in patients with chronic rhinosinusitis with nasal polyps is associated with clinical-cytological grading severity.伴有鼻息肉的慢性鼻-鼻窦炎患者的嗅觉功能障碍与临床-细胞学分级严重程度相关。
Acta Otorhinolaryngol Ital. 2019 Oct;39(5):329-335. doi: 10.14639/0392-100X-2426.
6
EUFOREA consensus on biologics for CRSwNP with or without asthma.EUFOREA 共识:针对伴有或不伴哮喘的 CRSwNP 使用生物制剂。
Allergy. 2019 Dec;74(12):2312-2319. doi: 10.1111/all.13875. Epub 2019 Jul 15.
7
Asthma Endotyping and Biomarkers in Childhood Asthma.儿童哮喘的内型分类及生物标志物
Pediatr Allergy Immunol Pulmonol. 2018 Jun 1;31(2):44-55. doi: 10.1089/ped.2018.0886.
8
Prevention of chronic rhinosinusitis.慢性鼻-鼻窦炎的预防。
Rhinology. 2018 Dec 1;56(4):307-315. doi: 10.4193/Rhin17.027.
9
Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach.基于临床-细胞学分级的鼻息肉慢性鼻-鼻窦炎非手术治疗:一种基于精准医学的方法。
Acta Otorhinolaryngol Ital. 2017 Feb;37(1):38-45. doi: 10.14639/0392-100X-1417.
10
Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis.鼻息肉型慢性鼻-鼻窦炎内镜鼻窦手术后息肉复发的患病率
Laryngoscope. 2017 Mar;127(3):550-555. doi: 10.1002/lary.26391. Epub 2016 Nov 12.

慢性鼻-鼻窦炎伴鼻息肉:如何在临床实践中确定适合使用生物制剂的患者。

Chronic rhinosinusitis with nasal polyps: how to identify eligible patients for biologics in clinical practice.

机构信息

Department of Otolaryngology, University of Foggia, Italy.

UOC of Otolaryngology Hospital Maggiore of Bologna, Italy.

出版信息

Acta Otorhinolaryngol Ital. 2022 Feb;42(1):75-81. doi: 10.14639/0392-100X-N1699.

DOI:10.14639/0392-100X-N1699
PMID:35292789
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9058935/
Abstract

OBJECTIVE

This study compared three severity measures for chronic rhinosinusitis with nasal polyps (CRSwNP). The outcome was to identify patients who are eligible for biological therapy.

METHODS

330 adult patients with CRSwNP were examined. Nasal polyp score (NPS), sinonasal outcome test (SNOT-22) and clinical-cytological grading (CCG) were compared. Clinical history, past surgery and asthma control test were also considered.

RESULTS

Only 45 (13.6%) patients had a contextual positivity to the three severity measures. The concordance among tests was slight/fair. Patients with severe disease (all tests positive) had more impaired parameters. The mixed cytotype (OR = 4.07), nasal obstruction (OR = 10.06), post-nasal drip (OR = 1.98), embarrassment (OR = 2.53) and difficulty falling asleep (OR = 1.92) were significantly associated with severe CRSwNP.

CONCLUSIONS

To identify candidates for biological therapy, the contextual use of NPS, SNOT-22 and CCG is preferable. In this way, global assessment of CRSwNP, including morphology, inflammation, comorbidity, symptoms and quality of life is possible.

摘要

目的

本研究比较了三种慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)严重程度评估方法。旨在确定适合生物治疗的患者。

方法

对 330 例 CRSwNP 成年患者进行检查。比较鼻息肉评分(NPS)、鼻鼻窦结局测试-22 项(SNOT-22)和临床细胞学分级(CCG)。还考虑了临床病史、既往手术和哮喘控制测试。

结果

仅 45 例(13.6%)患者的三种严重程度评估方法均呈阳性。测试之间的一致性为轻度/中度。患有严重疾病(所有测试均为阳性)的患者,其参数受损更严重。混合细胞型(OR=4.07)、鼻塞(OR=10.06)、后鼻滴注(OR=1.98)、尴尬(OR=2.53)和入睡困难(OR=1.92)与严重 CRSwNP 显著相关。

结论

为了确定生物治疗的候选者,最好根据具体情况使用 NPS、SNOT-22 和 CCG。这样,可以对 CRSwNP 进行全面评估,包括形态、炎症、合并症、症状和生活质量。